{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=schizophrenia%2Fschizoaffective+disorder.&page=9",
    "query": {
      "intervention": "schizophrenia/schizoaffective disorder.",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 234,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=schizophrenia%2Fschizoaffective+disorder.&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=schizophrenia%2Fschizoaffective+disorder.&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T14:51:32.217Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05601063",
      "title": "Ascertaining Diagnosis Classification With Elicited Speech",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia Spectrum and Other Psychotic Disorders",
        "Bipolar and Related Disorders",
        "Depressive Disorder",
        "Anxiety Disorders",
        "Personality Disorders",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Winterlight Speech Assessment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "14 Years to 50 Years"
      },
      "enrollment_count": 255,
      "start_date": "2020-10-01",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-01",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05601063"
    },
    {
      "nct_id": "NCT00261716",
      "title": "Motivational Interviewing to Improve Work Outcomes in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizoaffective Disorder",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "IPS",
          "type": "BEHAVIORAL"
        },
        {
          "name": "IE",
          "type": "BEHAVIORAL"
        },
        {
          "name": "VOMI",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2005-01",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2016-08-03",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "West Los Angeles, California",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00261716"
    },
    {
      "nct_id": "NCT00108303",
      "title": "Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Diagnostic",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "1 Year to 79 Years"
      },
      "enrollment_count": 538,
      "start_date": "2004-01",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2016-01-07",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108303"
    },
    {
      "nct_id": "NCT00206102",
      "title": "A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "quetiapine fumarate",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1098,
      "start_date": "2003-09",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-14",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 63,
      "location_summary": "Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mabelvale",
          "state": "Arkansas"
        },
        {
          "city": "Morrilton",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206102"
    },
    {
      "nct_id": "NCT05779241",
      "title": "Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "LYN-005",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lyndra Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 83,
      "start_date": "2023-04-13",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 5,
      "location_summary": "Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05779241"
    },
    {
      "nct_id": "NCT00330551",
      "title": "Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Oral Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Risperidone in Long-Acting Injectable Form (Consta)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 126,
      "start_date": "2006-03",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00330551"
    },
    {
      "nct_id": "NCT02254733",
      "title": "Assertive Community Treatment With CBT and SST for Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Social Skills Training (CBSST)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Assertive Community Treatment (ACT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Veterans Medical Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2012-02",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-17",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02254733"
    },
    {
      "nct_id": "NCT00942981",
      "title": "Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizoaffective Disorder",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "PET",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 283,
      "start_date": "2009-11-13",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942981"
    },
    {
      "nct_id": "NCT04951700",
      "title": "Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Aging",
        "Disease Course",
        "Biomarker",
        "Neuroimaging",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Other",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 194,
      "start_date": "2021-07-01",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-21",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04951700"
    },
    {
      "nct_id": "NCT01074632",
      "title": "Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder"
      ],
      "interventions": [
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2009-05",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2011-09-08",
      "last_synced_at": "2026-10-13T14:51:32.217Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Wichita, Kansas",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01074632"
    }
  ]
}